REPROCELL
Chirag Tawde has had a diverse work experience in the life sciences industry. Chirag began their career at STEMCELL Technologies, where they worked as a Technical Sales Representative from September 2008 to November 2011. Chirag then transitioned to the role of an Account Manager from September 2011 to April 2014. In 2014, Chirag joined DefiniGEN as a Commercial Manager, where they focused on providing disease modelled cellular products derived from human induced pluripotent stem cells. Chirag'stenure at DefiniGEN lasted until August 2015. Currently, Chirag is serving as the Sales Director EMEA at REPROCELL, a position they have held since September 2015.
Chirag Tawde completed their Bachelor of Science (Honors) in Biomedical Sciences at the University of Central Lancashire from 2004 to 2007. Chirag then pursued a Master of Science in Stem Cell Technology at the University of Nottingham from 2007 to 2008. Additionally, they obtained certifications in Conceptual Selling® and Strategic Selling® from Miller Heiman in September 2008.
This person is not in any offices
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.